Public Employees Retirement Association of Colorado Has $27.11 Million Stake in Cambrex Co. (CBM)

Public Employees Retirement Association of Colorado grew its holdings in shares of Cambrex Co. (NYSE:CBM) by 5.7% in the 3rd quarter, Holdings Channel reports. The fund owned 396,370 shares of the biotechnology company’s stock after purchasing an additional 21,313 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Cambrex were worth $27,112,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. BlackRock Inc. raised its stake in shares of Cambrex by 8.7% during the second quarter. BlackRock Inc. now owns 4,624,250 shares of the biotechnology company’s stock valued at $241,849,000 after acquiring an additional 370,806 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Cambrex by 3.8% during the second quarter. Bank of New York Mellon Corp now owns 1,471,966 shares of the biotechnology company’s stock valued at $76,982,000 after acquiring an additional 54,475 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Cambrex by 1.0% during the second quarter. Dimensional Fund Advisors LP now owns 1,420,580 shares of the biotechnology company’s stock valued at $74,295,000 after acquiring an additional 13,858 shares during the last quarter. American Capital Management Inc. raised its stake in shares of Cambrex by 6.7% during the second quarter. American Capital Management Inc. now owns 720,476 shares of the biotechnology company’s stock valued at $37,681,000 after acquiring an additional 45,312 shares during the last quarter. Finally, Boston Partners raised its stake in shares of Cambrex by 3.2% during the second quarter. Boston Partners now owns 699,286 shares of the biotechnology company’s stock valued at $36,572,000 after acquiring an additional 21,399 shares during the last quarter.

In related news, CEO Steven M. Klosk sold 20,000 shares of Cambrex stock in a transaction on Tuesday, October 23rd. The shares were sold at an average price of $54.76, for a total transaction of $1,095,200.00. Following the completion of the transaction, the chief executive officer now owns 103,328 shares of the company’s stock, valued at $5,658,241.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Samantha Hanley sold 27,500 shares of Cambrex stock in a transaction on Monday, August 6th. The stock was sold at an average price of $62.64, for a total transaction of $1,722,600.00. Following the transaction, the vice president now directly owns 2,500 shares of the company’s stock, valued at approximately $156,600. The disclosure for this sale can be found here. Insiders have sold 298,760 shares of company stock valued at $18,730,127 in the last three months. 2.42% of the stock is owned by insiders.



NYSE CBM traded down $0.15 during mid-day trading on Monday, reaching $53.08. 20,989 shares of the stock were exchanged, compared to its average volume of 372,871. Cambrex Co. has a one year low of $42.55 and a one year high of $69.43. The company has a market capitalization of $1.77 billion, a PE ratio of 16.79, a P/E/G ratio of 1.89 and a beta of 2.44.

Cambrex (NYSE:CBM) last announced its earnings results on Thursday, August 2nd. The biotechnology company reported $0.74 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.05. Cambrex had a net margin of 20.75% and a return on equity of 22.32%. The business had revenue of $152.05 million during the quarter, compared to the consensus estimate of $132.78 million. During the same quarter last year, the firm earned $0.76 earnings per share. Cambrex’s quarterly revenue was up 13.0% on a year-over-year basis. As a group, analysts anticipate that Cambrex Co. will post 2.82 earnings per share for the current year.

A number of equities analysts recently weighed in on CBM shares. ValuEngine raised shares of Cambrex from a “sell” rating to a “hold” rating in a research note on Friday, July 6th. Jefferies Financial Group started coverage on shares of Cambrex in a research note on Tuesday, September 25th. They set a “buy” rating and a $75.50 target price for the company. Finally, Zacks Investment Research raised shares of Cambrex from a “hold” rating to a “strong-buy” rating and set a $73.00 target price for the company in a research note on Wednesday, August 8th. Two investment analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. Cambrex has an average rating of “Buy” and a consensus price target of $69.50.

Cambrex Profile

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals.

Recommended Story: Moving Average (MA)

Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).

Institutional Ownership by Quarter for Cambrex (NYSE:CBM)

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply